A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide

BACKGROUND: In metastatic castration-resistant prostate cancer (mCRPC), assessing treatment response and bone lesions with technetium-99m is limited by image resolution and subjectivity. We evaluated bone scan lesion area (BSLA), a quantitative imaging assessment of response in patients with mCRPC r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ESMO Open
Main Authors: Petrylak, D.P., Vaishampayan, U.N., Patel, K.R., Higano, C.S., Albany, C., Dawson, N.A., Mehlhaff, B.A., Quinn, D.I., Nordquist, L.T., Wagner, V.J., Siegel, J., Trandafir, L., Sartor, O.
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2021
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7985394/
https://ncbi.nlm.nih.gov/pubmed/33744812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.esmoop.2021.100082
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados